Are you Dr. Rodig?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
75 Francis St
Brigham & Women's Hospital, Dept. Of Pathology, Amory 3
Boston, MA 02115Phone+1 617-732-7510
Summary
- Dr. Scott Rodig, MD is a board certified pathologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is an Associate Professor at Harvard Medical.
Education & Training
Washington University in St. Louis School of MedicineClass of 1998
Certifications & Licensure
MA State Medical License 2002 - 2027
American Board of Pathology Anatomic Pathology- American Board of Pathology Hematology
Publications & Presentations
PubMed
- 1 citationsCirculating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab.Jiajia Chen, Giuseppe Tarantino, Mariano Severgnini, Joanna Baginska, Anita Giobbie-Hurder
Oncoimmunology. 2025-12-01 - Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D.Jonathan D Schoenfeld, Nilofer S Azad, Jacob Gross, Li Chen, Michael J Overman
Clinical Cancer Research. 2025-02-17 - Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma.Julia Schiantarelli, Mouadh Benamar, Jihye Park, Haley E Sax, Giacomo Oliveira
Cancer Cell. 2025-02-10
Press Mentions
New Research Shows Which Ovarian Cancer Patients Won't Benefit from Immune-PARP ComboMarch 19th, 2020
Research Update: Biomarkers as Predictors of Immunotherapy Response in MelanomaSeptember 13th, 2018
Study Finds Melanoma Biomarkers Predicting Checkpoint Blocker ResponseJuly 18th, 2018- Join now to see all
